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Amylinergic control of food intake in lean and obese
rodents
Abstract
Obesity develops despite a complex and seemingly well orchestrated network that controls
eating, energy expenditure and ultimately body weight; many of the involved signals are
derived from the gastrointestinal tract. It is assumed that this network as an entity aims at
maintaining body weight and body adiposity at a relatively constant level, but the control
mechanisms seem to fail at least if an individual is chronically exposed to an oversupply of
food. This article summarizes recent findings about the role of amylin in the control of eating
in lean and obese rodents. The article gives some short background information about the well
investigated adiposity and satiating signals leptin and cholecystokinin, respectively; this will
provide the framework to discuss aspects of amylin physiology and pathophysiology in the
control of eating in leanness and obesity. This discussion also involves the mechanisms
mediating amylin's eating inhibitory effect in the area postrema and the interactions between
amylin and leptin. Further, we discuss the effect of high fat diets on amylin release and amylin
action in lean and obese rats. The last part of this article raises the question whether amylin
interacts with the reward system in the forebrain.
1 
 
  
 
 
 
 
Amylinergic control of food intake in lean and obese rodents  
 
Christina N. Boyle and Thomas A. Lutz 
 
Institute of Veterinary Physiology and Zurich Center for Integrative Human 
Physiology, Vetsuisse Faculty University of Zürich, Switzerland. 
 
Corresponding author: 
Thomas Lutz 
Institute of Veterinary Physiology 
Vetsuisse Faculty University of Zürich 
Winterthurerstrasse 260 
8057 Zürich 
Switzerland 
Phone: +41 44 6358808 
Fax: +41 44 6358932 
Email: tomlutz@vetphys.uzh.ch 
Keywords: amylin; satiation; adiposity; high-fat; hyperamylinemia; reward 
2 
 
ABSTRACT 
 
Obesity develops despite a complex and seemingly well orchestrated network 
that controls eating, energy expenditure and ultimately body weight; many of the 
involved signals are derived from the gastrointestinal tract. It is assumed that this 
network as an entity aims at maintaining body weight and body adiposity at a 
relatively constant level, but the control mechanisms seem to fail at least if an 
individual is chronically exposed to an oversupply of food. This article 
summarizes recent findings about the role of amylin in the control of eating in 
lean and obese rodents. The article gives some short background information 
about the well investigated adiposity and satiating signals leptin and 
cholecystokinin, respectively; this will provide the framework to discuss aspects 
of amylin physiology and pathophysiology in the control of eating in leanness and 
obesity. This discussion also involves the mechanisms mediating amylin’s eating 
inhibitory effect in the area postrema and the interactions between amylin and 
leptin. Further, we discuss the effect of high fat diets on amylin release and 
amylin action in lean and obese rats. The last part of this article raises the 
question whether amylin interacts with the reward system in the forebrain.
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Introduction 
The maintenance of food intake and body weight is primarily controlled by a 
complex neural network comprising the hypothalamus and the hindbrain, which is 
also thought to be influenced by reward regions such as the nucleus accumbens 
and the ventral tegmental area.  These brain nuclei not only communicate with 
each other, but they also receive and integrate neural and humoral information 
generated in the gut and other peripheral organs, which reflect the dynamic 
energy status and needs of the organism. Research from the past two decades 
suggests that while this system is well in balance to maintain energy 
homeostasis when an organism experiences daily moderate fluctuations in food 
intake, or even challenged by more severe circumstances such as occasional 
cycles of feast and famine, it is not designed to cope with prolonged periods of 
energy excess [1]. So, what exactly is happening in these networks, and in the 
periphery, when intake of highly palatable and energy–dense foods outweighs 
energy expenditure, resulting in obesity? 
 
It is well-established that obesity leads to elevated circulating levels of adiposity 
signals, such as insulin and leptin, which in turn leads to insulin- and leptin-
resistance.  Increased levels of adiposity and of adiposity signals can also 
modulate the release and sensitivity to various gut hormones involved in the 
control of energy balance, including glucagon-like peptide-1 (GLP-1), 
cholecystokinin (CCK), and amylin. More recent evidence suggests that obesity 
and exposure to foods high in fat may actually modify the wiring of this central 
network, potentially contributing to the insensitivity to many of these adiposity 
signals thought to prevent excess fat accumulation.   
 
This review focuses on the specific role of amylin in this network. Various 
aspects of amylin release and sensitivity are discussed in the framework laid out 
by examples from the literature depicting how obesity or a high fat diet can 
modify central signaling of adipose and gut-derived hormones, in particular leptin 
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and CCK. Based on the background of leptin’s and CCK’s roles in this network, 
we summarize recent studies on amylin physiology and pathophysiology.  
 
Lessons learned from leptin 
Leptin, a hormone primarily produced and secreted by adipose tissue, produces 
its effects on food intake and body weight by acting on the long form leptin 
receptor (LRb), which is located throughout the central nervous system; notably, 
it is present in the hypothalamic arcuate nucleus (ARH), the lateral hypothalamic 
area (LHA), the ventromedial nucleus of the hypothalamus (VMH), the 
dorsomedial nucleus of the hypothalamus (DMH), the ventral tegmental area 
(VTA), and the nucleus of the solitary tract (NTS) [2-5].  A large number of 
publications indicate that leptin may influence eating and energy metabolism via 
these multiple brain sites (summarized in [6]) but the necessity or sufficiency of 
leptin receptors in these brain areas for leptin action is only incompletely 
understood.  While the phenotype of many of these LRb-expressing neurons 
remains unclear, leptin receptors in the ARH are expressed by two distinct 
populations: pro-opiomelanocortin (POMC)-containing neurons and neuropeptide 
Y (NPY)- and agouti-related peptide (AgRP)-containing neurons [7, 8].  Elevated 
levels of leptin stimulate POMC expression, activating the melanocortin network 
to inhibit food intake [9, 10].  In contrast, leptin inhibits the production of AgRP 
and NPY, which also reduces the drive the feed induced by these peptides [11]. 
 
Janus Kinase-2 (Jak2) is activated when leptin binds to LRb. Jak2 activation 
leads to autophosphorylation and to the phosphorylation of various tyrosine 
residues located on the intracellular domain of the LRb.  The phosphorylation of 
these residues leads to the activation of several signaling pathways.  One 
pathway involves the phosphorylation of signal transducer and activator of 
transcription-3 (STAT3), following which this transcription factor translocates into 
the nucleus to regulate gene expression.  The presence of phosphorylated 
STAT3 (pSTAT3) is often used as a marker of LRb functionality, because at least 
in the ARH, STAT3 is required for leptin-induced POMC expression [12].  STAT3 
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also regulates suppressor-of-cytokine-signaling-3 (SOCS-3), which acts as a 
negative feedback signal to inhibit LRb activity.  Leptin binding to LRb can also 
lead to the activation of signal transducer and activator of transcription-5 (STAT5) 
and extracellular signal-regulated kinase (ERK) signaling pathways, and leptin is 
known to inhibit AMP-activated protein kinase in both the ARH and the 
paraventricular nucleus of the hypothalamus (PVH), as well as in the NTS of the 
hindbrain [13, 14].  Except for the pSTAT3 and SOCS-3 pathways, the functional 
relevance of the other intracellular signaling systems is largely unknown [6]. 
 
Obesity and leptin resistance 
At the time of its discovery, leptin was thought to potentially be the answer to the 
obesity epidemic.  However, it was soon recognized that while obese Lepob/ob 
mice which lack leptin remain very sensitive to leptin and lose weight when 
treated with exogenous leptin, most obese humans and rodents are not deficient 
in leptin, and actually demonstrate elevated levels of the circulating hormone.  It 
is now known that obesity-induced hyperleptinemia contributes to leptin 
resistance (summarized in [6]), which in turn renders exogenous leptin quite 
ineffective in treating common obesity. Leptin-induced leptin resistance may be 
due to increased SOCS-3 induction, shifting the balance between pSTAT3 
activation (and hence increased signaling) and SOCS-3 induction (which limits 
leptin action). However, the exact mechanism by which leptin resistance occurs 
is not understood, and a reversal of this resistance could potentially be very 
beneficial in the treatment of obesity.  
 
Leptin resistance is typically characterized by a lack of behavioral or cellular 
responses to exogenously administered leptin at doses that produce effects in 
lean animals.  Thus rodents that do not demonstrate a decrease in food intake or 
body weight, or an activation of leptin signaling pathways (e.g. phosphorylation of 
STAT3) when injected with leptin are classified as leptin resistant.  Proposed 
causes of leptin resistance include defective leptin receptor signaling, defective 
6 
 
neuronal signaling downstream of the LRb, and decreased leptin transport 
across the blood brain barrier (summarized in [6]). 
 
Most rodent models of leptin-resistance depend on an obese state, which is 
typically achieved by maintaining the animals on a high-fat diet (HFD). Obese 
rodents first develop resistance to peripherally injected leptin, and with prolonged 
access to a HFD, resistance to centrally injected leptin also emerges [15]. Most 
mice and rats will gain adiposity when placed on a HFD containing 60% of 
calories from fat; interestingly, when maintained on a more moderate HFD (~30% 
calories from fat), some strains, notably Sprague-Dawley (SD) rats, will 
demonstrate a bimodal pattern of body weight gain which results in clearly 
distinct diet-induced obesity (DIO)-prone and –resistant (DR) subpopulations 
[16].  Experiments utilizing outbred rodents maintained on HFD can assess the 
role of the diet on changes in central networks controlling homeostasis. 
Additionally, experiments involving, for example, SD rats selectively-bred to be 
DIO or DR can assess underlying traits that predispose these animals to obesity 
prior to any access to a diet high in fat [17].  Use of both the outbred and 
selectively bred DIO and DR rodents has shed considerable light on how HFD, or 
the genetic predisposition to gain fat when fed a HFD, alters leptin sensitivity. To 
name just one example, adult DIO rats show reduced expression of LRb mRNA, 
decreased leptin binding, and demonstrate decreased STAT3 phosphorylation 
when being administered leptin [18-20]. 
 
Decreased leptin-induced pSTAT3 activation is typically used as a correlate for 
cellular leptin resistance. In general, any decrease in intracellular LRb signaling 
is part of cellular leptin resistance which also occurs in DIO. As already 
mentioned, increased SOCS-3 contributes to an overall attenuation of leptin 
signaling. Another intracellular event associated with reduced leptin action is an 
increase of protein tyrosine phosphatase 1B (PTP1B); the mechanism how leptin 
increases PTP1B is unknown but PTP1B, similar to SOCS-3, decreases JAK2 
phosphorylation and subsequently LRb signaling [21]. Interestingly, both SOCS-3 
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and PTB1B seem to be upregulated by high-fat feeding which may at least in part 
explain the link between increased dietary fat and leptin resistance [22, 23]. 
 
It is still a matter of debate whether leptin reaches its target neurons directly or 
whether it needs to be transported across the blood-brain barrier. Such transport 
into the brain by a saturable, regulated transporter may in fact play a role in the 
development of leptin resistance [24]. DIO rats have a reduced ratio of 
cerebrospinal fluid (CSF) leptin versus serum leptin; hence, the amount of leptin 
that reaches the LRb may not be sufficient for leptin action in obese [25]. Studies 
showing that central injections of leptin can at least partly improve leptin 
sensitivity in DIO rats are in line with the idea that defective leptin transport 
represents one component in leptin resistance [15, 26]. Diets high in fat, which 
obviously contribute to DIO, or elevated triglycerides may also decrease leptin 
transport directly [27]. 
 
Leptin’s effects on hypothalamic neuronal connection development 
Recent evidence suggests that changes in circulating leptin levels alter signaling 
in the adult rodent brain, and that consumption of a HFD can actually modify how 
leptin-sensitive networks of the ARH are organized [28-30].  Interestingly, 
changes in circulating leptin also play a role in the development of critical 
connections within the central network controlling energy homeostasis in rodent 
pup brains. By using DiI to label the developing axonal connections between 
leptin-sensitive ARH and other hypothalamic nuclei, Bouret and colleagues have 
elegantly shown that leptin is required for the normal development of neuronal 
connections between the ARH and PVH, the DMH, and the LHA [31].  Leptin-
deficient Lepob/ob mouse pups show a significant decrease in fiber density of ARH 
projections to these hypothalamic targets compared to their wild type littermates 
at various points of postnatal development.  This decrease can be rescued, 
however, when neonatal pups are treated with exogenous leptin [31].  It is 
interesting to consider that despite this decrease in the outgrowth of leptin-
sensitive ARH neurons, Lepob/ob mice remain very responsive to the weight-
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reducing effects of leptin as adults.  Maintenance of leptin sensitivity in adult 
Lepob/ob mice suggests at least two possible explanations. This phenomenon can 
be potentially explained by the fact that not all leptin-sensitive pathways are 
defective in Lepob/ob mice, particularly projections from the PVH and DMH [31]; 
these additional leptin-sensitive projections may compensate for the lack of ARH 
projections in congenital leptin deficiency. Alternatively, this may question the 
relevance (or necessity) of these ARH to PVH projections for leptin's behavioral 
effects in general. 
  
More recent data showed that the disruption in ARH projections is not limited to 
leptin-deficient or leptin-receptor deficient rodents [32].  Selectively bred DIO SD 
pups also show significant reductions in ARH to PVH projections [33]. This effect 
is further carried into adulthood, as these rats show decreased AgRP-
immunoreactive fibers in the PVH, suggesting a decrease in NPY/AgRP activity 
in this ARH target site [33].  Because adult DIO rats have been described as 
having reduced LRb expression and leptin binding [18, 19], it is possible that 
these traits may contribute to the blunted development of these projections, and 
eventually to the low leptin sensitivity seen in these animals. Of note, it was 
recently shown that selectively bred DIO pups are not necessarily fated to 
become obese.  DIO pups reared in large litters (16 vs. 10 pups/dam) are not 
only protected from becoming obese adults, but also show increased AgRP-
immunoreactive fibers in the PVH and elevated leptin-receptor binding in the 
ARH [34]. These studies indicate that the development of the neuronal network 
that is involved in the control of eating seems to depend on prenatal, most likely 
genetic, factors, but also on the postnatal environment, potentially via epigenetic 
effects. 
 
Effects of diet and obesity on CCK 
In addition to modifying adiposity signals, like leptin, obesity reportedly alters the 
efficacy of satiating factors as well.  Cholecystokinin (CCK), which is mainly 
produced in the duodenum and jejunum, and which is rapidly released in 
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response to local nutrients, is considered the prototypical satiation signal [35, 36].  
CCK acts on vagal afferents, which project to the NTS in the hindbrain, and 
administration of CCK to humans and animals inhibits food intake by reducing 
meal size and duration [35, 37]. The idea that a diet high in fat might modify the 
effects of satiating hormones, particularly CCK, was first addressed by Covasa 
and Ritter [38]. They demonstrated that peripheral administration of CCK 
reduced food intake significantly less in rats adapted to a diet containing at least 
34% fat by weight, than in rats maintained on a low fat diet (5% by weight).  They 
also showed using isocaloric diets that this effect was specific to the increased 
ingestion of fat, and not just caused by a higher energy intake [38]. Interestingly, 
the HFD was also shown to reduce CCK-induced inhibition of gastric emptying in 
rats. This effect was also observed if rats on a low fat diet were infused 
intraduodenally with oleate [39], once again indicating a critical role of fat 
ingestion in the blockade of CCK’s effects.  HFD-induced reduction in CCK 
sensitivity is also accompanied by decreased neuronal c-Fos expression in the 
NTS following CCK administration, supporting the hypothesis that HFD reduces 
vagal responsiveness to CCK [40].  
 
Amylin signaling 
The previous paragraphs shortly summarized reports on how the effectiveness of 
leptin and CCK may be affected by adiposity or by specific feeding situations, 
such as exposure to high-fat diets. Similar phenomena may also be relevant for 
other signals involved in the control of energy balance. Understanding these 
phenomena is important to develop effective and safe treatments for obesity. In 
the following, we therefore discuss newly elaborated aspects of amylin 
physiology and pathophysiology in the control of eating in leanness and obesity. 
Amylin is secreted from the pancreatic -cells in response to nutrient 
consumption.  Amylin plays a critical role in the control of nutrient flux and 
postprandial glucose regulation, and has inhibitory effects on gastric acid 
secretion, gastric emptying, pancreatic glucagon secretion, digestive enzyme 
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secretion, and eating [reviewed in 41, 42].  The most investigated function of 
amylin is its role as a physiological signal of satiation.  Peripheral amylin 
administration quickly and dose-dependently inhibits eating in rats, causing a 
decrease in meal size, while having no effect on the subsequent intermeal 
interval [43, 44]. The satiating effect of peripheral amylin seems to be mediated 
by neurons in the area postrema (AP), a circumventricular organ located in the 
caudal hindbrain.  Lesions of the AP, but not blockade of neural afferents 
projecting to the brain, abolish amylin’s inhibitory effect on eating in rats [45, 46].  
The role of the AP in mediating amylin’s actions seems not restricted to the 
eating inhibitory effect because amylin’s effect to inhibit gastric emptying is also 
absent in AP-lesioned rats [47].  Injection of the amylin antagonist, AC187, into 
the AP stimulates eating by an increase in meal size [48].  Furthermore, 
electrophysiological and immunohistochemical studies confirmed the direct 
influence of amylin on AP neurons [49-52].  Functional amylin receptors comprise 
a calcitonin receptor (CT-R) core and receptor-activity modifying proteins 
(RAMPs) [53, 54].  RAMPs regulate transport of core receptors to the cell 
surface, and are involved in ligand specificity of the receptor.  All components of 
the amylin receptor, including the CT-R, RAMP1, and RAMP3, are expressed in 
the AP [55, 56].   
While the exact signaling pathway of amylin is unclear, work from our laboratory 
provides evidence for the role of specific intracellular pathways in mediating 
amylin action [49, 57, 58].  Amylin, like other satiating hormones, induces a 
strong c-Fos response in distinct brain nuclei, including the AP, NTS and lateral 
parabrachial (PBl); however, it is important to mention that the functional 
relevance of c-Fos activation in all these cases is unknown [51, 59]. More recent 
data indicate that exogenous amylin administration induces both the 
accumulation of cyclic guanosine monophosphate (cGMP) and the 
phosphorylation of ERK (pERK) in the AP [49, 57, 58]; both may be involved in 
mediating effects of amylin on food intake, but the necessity of these events for 
amylin’s satiating properties is still being delineated.  
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The noradrenergic neurons also play a critical role in encoding amylin information 
from the AP to other regions of the hindbrain and the forebrain, as neurotoxic 
lesions of these neurons result in a reduction in the hypophagic effect of 
exogenous amylin [60].  Noradrenergic neurons in the AP send significant 
projections to the PBl, which potentially acts as a key relay station between the 
hindbrain and the hypothalamus [57, 61].  The PBl, which demonstrates strong 
amylin-induced c-Fos [51] and is required for the full induction of amylin’s 
anorectic effect [62], sends projections to the LHA, ARH, VMH, DMH, and the 
PVH [61].  Two other forebrain nuclei receiving projections from the PBl and 
activated by amylin administration include regions of the bed nuclei of the stria 
terminalis (BST) and the central nucleus of the amygdala (CEA) [51, 52, 61]. 
Induction of c-Fos in the CEA requires an intact PBl [63], however the 
involvement of the CEA or the BST in the behavioral effects of amylin remains 
undefined. 
In addition to amylin’s role as a satiation factor, amylin meets the main criteria to 
be considered an adiposity signal.  Similar to leptin and insulin, the basal 
circulating level of amylin correlates positively with adipose mass [64]; the basal 
plasma levels of amylin are higher in obese rodents, but amylin levels throughout 
the development of obesity have typically not been reported [64, 65].  Basal and 
glucose-stimulated plasma amylin levels are also elevated in obese humans [66, 
67]. In principle, these findings support an association between body adiposity 
and plasma amylin. Future studies will have to test whether changes in body 
adiposity result directly in changing amylin levels, and whether adiposity and 
amylin levels follow the same temporal pattern (see [68] for further discussion).   
 
Chronic amylin infusion reduces food intake and body weight, primarily caused 
by a decrease in spontaneous meal size [44], and chronic central amylin infusion 
lowers body weight in both under- and overweight rats [69], i.e. irrespective of 
prior manipulation of body weight.  The decrease in body mass was specifically 
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due to a reduction in body adiposity. Overall, these experiments suggest that the 
central amylin level appears to be an important determinant for the attained level 
of body weight or body adiposity. Additionally, and in support of this hypothesis, 
chronic peripheral or central infusion of amylin antagonists increases body weight 
and body fat mass [70].  Finally, the amylin knockout mouse is heavier than 
wildtype controls [71], but it is not yet known whether amylin replacement 
reverses this phenotype, as would typically be expected. 
Together, these data present amylin as a putative adiposity signal, and suggest 
that amylin secretion may also be altered by increased body adiposity.  However, 
it remains unclear how adiposity modifies amylin sensitivity and function; further, 
it is unclear whether amylin’s role as satiating and as adiposity signals are 
processed differently by the brain [72]. 
 
Amylin and leptin interactions 
There is a growing body of evidence supporting the existence of amylin and 
leptin interactions in the regulation of energy homeostasis.  In response to acute 
administration, central leptin increased the acute eating-inhibitory effect of 
peripheral amylin in rats [73]. Similar obervations were reported in more chronic 
experimental designs.  While non-genetically obese rodents and humans are 
generally not sensitive to the weight-reducing effects of leptin, when leptin is co-
administered with amylin, or its analog pramlintide, greater weight loss can be 
achieved than if either peptide were administered alone [74]. Amylin appeared to 
overcome the leptin insensitivity of obese rats and restore leptin sensitivity to 
normal. The body weight loss in rats that were pair-fed to the amylin-treated rats 
and that only received leptin was not more pronounced than in rats that were 
infused with amylin alone. In other words, additional exogenous amylin was 
necessary to increase the potency of leptin and to reduce the body weight gain in 
obese rats. 
Further analysis demonstrated that the interaction between amylin and leptin to 
reduce body weight is synergistic, and not just additive [75].  Pair-fed control rats, 
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matched to rats treated with amylin and leptin for 28 days, demonstrated that the 
weight loss induced by the combination treatment was primarily a function of 
decreased food intake, though the combination treatment did yield a significantly 
greater percentage of fat mass loss than pair-feeding [75].  The study also 
revealed that leptin and amylin co-administration resulted in preferential 
utilization of fat as an energy substrate, and that decreased hepatic lipogenesis 
and increased lipid utilization may also underlie the weight loss effects [75]. 
While the mechanisms underlying amylin/leptin synergy are not entirely 
understood, it has been proposed that the two hormones share common 
neuronal pathways to generate such an effect on body weight [76].  Initial studies 
showed that while DIO rats did not mount a hypothalamic pSTAT3 response to 
peripherally administered leptin, pretreatment with amylin for seven days 
restored STAT3 phosphorylation in parts of the hypothalamus (e.g., the VMH), 
but not in the hindbrain [74]. It appears unlikely that the AP, amylin’s primary 
direct target region, is directly involved in the amylin/leptin interaction. After 
single injections, leptin did not enhance the amylin-induced activation of AP 
neurons as gauged by c-Fos expression [76]. Further, rats that were pretreated 
with amylin for one week showed increased pSTAT3 formation in the AP after 
acute leptin [74], but the effect was relatively weak and a very large dose of leptin 
was utilized in that study.  
Based on our and other studies [74, 76], we therefore believe that the 
amylin/leptin interaction resides in the hypothalamus, presumably after 
polysynaptic input from the AP. Amylin increased the effect of leptin to induce 
pSTAT3 formation in the ARH in lean rats [76], and at least high doses of leptin 
resulted in increased pSTAT3 signaling in the VMH in obese, amylin-pretreated 
rats [74]. In other words, amylin restored the leptin-induced immunoreactivity of 
pSTAT3 in the VMH of obese rats to a level that is seen in leptin-treated lean 
rats.  These results are consistent with data showing that acute amylin treatment 
upregulated leptin receptor expression about 3-fold in the rat hypothalamus [72]. 
Further, leptin binding as determined by receptor autoradiography in the rat brain 
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was increased in the ARH by combination treatment with amylin and leptin, and it 
was increased by amylin alone in the VMH and the DMH [76]. Finally, these 
results are also consistent with reduced leptin receptor expression in the 
mediobasal hypothalamus in amylin-deficient mice [76]. It is plausible that the 
effects of amylin on pSTAT3 expression and leptin receptor expression are 
causally linked and are part of a common neuromechanism, but this has not 
been investigated yet. 
The finding that amylin and leptin may at least in part interact via the VMH is also 
interesting in the context of our previous studies that showed that amylin’s 
eating-inhibitory effect in rats is reduced by administration of the histamine H1 
receptor antagonists pyrilamine or chlorpheniramine into the VMH [77]; further, 
the acute effects of both amylin and leptin on eating were blunted in H1 receptor-
deficient mice [78, 79]. Hence, the potential role of histamine and of H1 receptors 
in the functional interaction of amylin and leptin in the VMH clearly deserves to 
be studied. 
Interestingly, the synergistic effect of amylin and leptin appears to be dependent 
on the extent of obesity.  The amylin and leptin synergy is not as evident nor as 
powerful in reducing body weight in severely obese rats (~800g) as compared to 
more mildly obese rats (~450g) [80], but amylin alone was still effective. In other 
words, amylin is not able to overcome extreme leptin resistance that may be 
associated with massive obesity. These findings have important clinical 
implications, suggesting that pharmacological treatments may differ for severely 
obese patients. Hence, it may be postulated that the synergy between amylin 
and leptin is most prominent within a designated range of body adiposity, but that 
amylin alone is still effective when higher pharmacological doses are 
administered chronically.  
 
Amylin sensitivity in the obese state 
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Provided our growing understanding of how adiposity signals and satiating 
hormones, like leptin and CCK, are affected by obesity and the chronic intake of 
diets high in fat, and given the therapeutic potential of amylin-based therapies, 
investigations into how amylin sensitivity may be altered by obesity or by the 
intake of HFD are imperative.  We recently tested the hypothesis that obesity 
reduces sensitivity to amylin. Furthermore, we evaluated if factors causing 
obesity (e.g., consumption of a high-fat or palatable diet) and factors associated 
with obesity (e.g., hyperamylinemia) lead to a change in amylin sensitivity, 
independently of obesity.  Our results suggest that amylin sensitivity is actually 
quite dynamic, depending on factors such as diet macronutrient composition, diet 
palatability and metabolic state [81, 82]. In all cases, at least high doses of 
amylin still caused a significant effect on eating.  
 
We first addressed if the acute anorexic response to amylin is altered in rats 
either maintained on a HFD to induce obesity or chronically food-restricted.  Over 
the course of the fourteen-week study, sensitivity to acute amylin injection was 
determined by injecting vehicle or amylin (5, 20, or 50 μg/kg, s.c.) and monitoring 
food intake.  We observed that when maintained on a 60% HFD (by calories), 
rats retained amylin sensitivity comparable to rats fed a standard chow diet for up 
to eleven weeks, at which point the significant amylin-induced reduction in food 
intake was lost. These data demonstrate that intake of HFD diet alone does not 
seem to alter amylin sensitivity; rather, the metabolic changes that occur 
following prolonged HFD intake appear to modify amylin’s efficacy.  While it is not 
clear what accounts for the shift in amylin sensitivity following prolonged HFD, we 
did observe significant increases in visceral and subcutaneous adiposity in these 
rats, as well as increases in circulating leptin and amylin.  Elevated amylin does 
not appear to be solely responsible for the shift (see below), however, since 
plasma metabolites (e.g., free fatty acids or triglycerides) were not measured 
during the HFD feeding period, it remains unclear whether a change in 
metabolites or combined changes in metabolite and hormone levels may 
contribute to reduced amylin sensitivity. 
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The third cohort of rats, which was food restricted to 80% of the standard chow 
group and provided their daily allotment of chow immediately following amylin 
administration, showed a strong resistance to amylin’s effects.  However, if the 
food-restricted rats were pre-fed prior to administration of a high dose of amylin, 
sensitivity was restored and food intake was significantly reduced.  This suggests 
that strong restriction-induced hunger signals can override amylin-induced 
satiation in an acute, short-term experiment.  This observation is consistent with 
an earlier study showing that hypoglycemia can reduce the amylin-induced 
slowing of gastric emptying, suggesting that certain physiological states can 
override some effects of amylin [83].  
 
These findings showing that amylin sensitivity seems shifted based on metabolic 
status are also interesting in the context of the reported amylin and leptin 
interactions; DIO rats maintained on a HFD for up to fourteen weeks, and food 
restricted rats, which have either very high or very low circulating leptin levels, 
respectively, were the least responsive to acute amylin administration.  Thus, 
though amylin sensitivity is evident in even very obese rodents chronically 
administered with relatively high doses of amylin, it is possible that optimal 
amylin responsiveness occurs within a specific range of body adiposity and/or 
circulating plasma leptin levels. 
 
We have also collected behavioral data suggesting that food palatability can alter 
amylin sensitivity, at least temporarily.  When naïve rats are fed palatable 
chocolate liquid Ensure, they demonstrate resistance to central or peripheral 
amylin (5 pmol, i3v or 5 μg/kg, i.p.) within the first three days of Ensure access.  
However, if the rats are maintained on the Ensure for three weeks, or switched 
back to a chow diet, then amylin sensitivity was restored [81]. It is important to 
mention, however, that the intake of novel Ensure can be inhibited with higher 
doses of centrally administered amylin (10 or 100 pmol, i3v), suggesting that 
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Ensure does not cause amylin immunity, but rather causes a right-shift in the 
dose-response curve.   
 
It has been reported previously that the chocolate flavor of Ensure plays a critical 
role in why rats overeat when it is offered [84].  We also found that the chocolate 
flavor of the Ensure seems to be a key element in our effect, because three-day 
feeding with neutral-flavored Ensure, which is nutritionally identical to chocolate-
flavored Ensure, did not result in amylin resistance.  These results suggest that 
the novelty of the palatable Ensure creates a strong signal to ingest that reduces 
the satiating effects of acute amylin; this alludes to the possibility that amylin’s 
effect on food intake can be influenced by the rewarding properties of food. 
 
Finally, because rats maintained on 60% HFD demonstrated elevated circulating 
amylin levels in the study previously described, we addressed if hyperamylinemia 
is a contributor to decreased amylin sensitivity in obese rodents.  It was recently 
shown that hyperleptinemia is required for the induction of leptin resistance in 
rats [85], and increased circulating levels of CCK have also been implicated in 
reduced sensitivity to CCK administration [86].  Increased circulating levels of 
amylin are present in obese rats and humans [64, 66, 67, 87], and previous 
studies suggest that high circulating levels of amylin also reduce amylin’s ability 
to slow gastric emptying [47]. Thus, we hypothesized that in rats, in which 
circulating baseline amylin was increased through chronic amylin administration, 
the sensitivity to acute exogenous amylin administration would be decreased.  
Furthermore, we hypothesized that the reduction in amylin sensitivity is 
proportional to the amylin concentration of chronically infused rats. 
   
Hence, we chronically infused lean rats for one week with amylin to increase their 
baseline amylin concentration to levels typically observed in obesity (30-40 pmol/l 
versus 10-15 pmol/l in lean rats). We then challenged these rats with acute 
peripheral amylin and assessed subsequent food intake. Interestingly, and in 
contrast to our hypothesis, we observed that exogenous amylin administration 
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decreased food intake dose-dependently under all conditions; in other words, 
amylin acutely decreased eating to a similar extent in all rats, regardless of 
circulating amylin levels [82]. While chronic infusion of physiological doses of 
amylin did cause subtle reductions in food intake and body weight, the data 
suggest that the rapid rise in circulating amylin following an acute injection, which 
more closely mimics meal-induced amylin release, may be more critical for 
amylin’s effect on food intake, regardless of prevailing basal amylin levels. Thus, 
at least under our experimental conditions, we saw no decrease in amylin 
sensitivity by chronically elevated amylin concentrations. Downregulation of 
amylin receptors or a decrease in post-receptor signaling following 
hyperamylinemia therefore appears to be unlikely. 
 
To summarize, we observed reduced amylin sensitivity under some but not all 
experimental conditions that, in the case of leptin, would typically be associated 
with leptin resistance.  While there is still much to be investigated, we believe that 
the mechanisms underlying the known instances of amylin and leptin insensitivity 
are likely to be quite different.  In the case of leptin resistance, central leptin 
receptor function is compromised, particularly in the ARH, the primary site of 
leptin action.  In contrast, at least when gauged by c-Fos expression, amylin 
induced AP activation, where amylin targets CT-Rs, is similar between rats fed 
standard chow or those fed HFD demonstrating either a DIO or DR profile.  Thus 
reduced amylin sensitivity may not be caused by direct changes in amylin 
receptor function. Future studies will have to investigate whether intracellular 
signaling systems like cGMP and pERK which seem to be involved in amylin 
action [49, 58], are affected by body adiposity or diet composition. Similar studies 
should also include other brain areas, which are activated subsequent to primary 
AP action; to mention just one example, it could be tested whether amylin-
induced noradrenaline release, which seems to be involved in mediating amylin 
action [60], is reduced in obese rats or in rats exposed to specific diets.  
 
Additionally, while decreased leptin transport across the blood brain barrier 
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appears to play a role in leptin resistance [25], amylin sensitivity is not likely 
regulated by BBB transport. Amylin crosses the BBB [88, 89], but the exact 
nature of this non-saturable transport or whether it is reduced in obesity is still 
unknown.  However, because much more evidence supports the notion that 
amylin exerts its effects on food intake and metabolism via the AP, which lacks a 
functional BBB, a change in amylin transport in obesity would likely be less 
influential on amylin action, as compared with changes in leptin and insulin 
transport across the BBB, which can profoundly alter their action [71, 90].   
 
Recent evidence suggests that hyperleptinemia is required for the development 
of leptin resistance [85], while the experiments discussed above show that lean 
rats, whose plasma amylin has been elevated and clamped to match that of 
obese rats, respond to acute amylin injections in a manner very similar to lean 
rats infused with saline [82].  Despite some potential differences in contributors to 
leptin and amylin insensitivity, it also should be noted that a decrease in amylin 
sensitivity may be related to changes in leptin sensitivity; namely, as suggested 
previously, that amylin controls energy homeostasis by engaging central 
networks downstream of the AP which are also employed by leptin.  Thus, when 
leptin resistance leaves these networks latent, or if leptin levels are too low to 
activate these networks, amylin may perhaps not work as efficiently. 
 
 
Amylin secretion in the obese state 
In addition to assessing amylin sensitivity, we have also recently looked at how 
obesity or maintenance on a HFD might alter amylin release in response to 
nutrient consumption. While it is known that basal levels of amylin are elevated in 
obese humans and in various rodent models of obesity, yet to be described is 
whether the meal-contingent release of amylin is affected by diet composition 
and, more importantly, whether the release pattern differs between obese and 
non-obese animals. Furthermore, the amylin-to-insulin concentration ratio, which 
is approximately 0.01 in lean humans and rodents [91, 92], is also elevated in the 
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obese state, but it has not been tested if this ratio is also affected by the diet 
composition of a meal and if the ratio specifically of the meal-contingent release 
is different in obese rats. To address these issue, we measured levels of amylin 
and insulin in hepatic portal vein blood samples collected from outbred SD rats 
maintained for eight weeks on either standard chow or HFD and classified as 
either DIO or DR. We observed that both diet and obesity affect amylin release.  
DR rats on the HFD that actually weighed less than the DIO and chow-fed rats, 
showed significantly elevated basal amylin levels, compared to chow-fed rats.  
Both HFD-fed groups, DR and DIO, demonstrated an earlier meal-induced rise in 
amylin concentration compared to the chow-fed group.  While insulin 
concentrations in response to a fixed-calorie meal were generally comparable 
between the groups, the slightly lower levels observed in the DR group did have 
an overall effect on the amylin:insulin ratio of the three groups. DR rats had 
significantly higher basal amylin:insulin concentration ratios than both DIO and 
chow-fed rats, and this ratio remained higher than the chow-fed rats during the 
meal. The differential meal-induced secretion patterns observed in DIO, DR, and 
chow-fed controls suggest that the ratio at which amylin and insulin are secreted 
during a meal is influenced by both body composition and diet composition 
(Boyle et al, unpublished observations).   
 
Though the specific drivers of change in amylin:insulin ratio need further 
investigation, our results are interesting in light of a recent report demonstrating 
that elevated fatty acids, which can result following long-term consumption of a 
diet high in fat, induce enhanced mRNA expression and release of amylin, but 
not insulin [93]. Furthermore, while the clinical relevance of the amylin:insulin 
secretory ratio remains largely unexplored, reports have shown that an elevated 
ratio is associated with chronic hyperglycemia in rats and with increased glucose 
intolerance in obese humans [94, 95]. 
 
Amylin as a trophic factor 
21 
 
We have also recently collected evidence that, like leptin, amylin during perinatal 
development may influence the formation of neuronal connections involved in 
food intake [96], specifically the development of projections from the AP to the 
NTS.  This phenomenon may be comparable to the effect of leptin in the 
hypothalamus [31, 33, 97].  Bouret and colleagues [31, 33, 97] showed that 
genetically leptin-deficient Lepob/ob mice and leptin-resistant DIO rats have 
deficient projections from the hypothalamic ARH to the PVH.  An early postnatal 
surge of leptin secretion, that is lacking in Lepob/ob mice, may be required for the 
normal development of the brain [31, 33].  
Using a similar methodology, we tested whether amylin may also be an important 
trophic factor for the normal development of the mouse brain, namely hindbrain 
projections from the AP to the NTS. In fact, genetically amylin-deficient mice had 
a markedly reduced density of AP-NTS projections compared with controls when 
tested on postnatal day 10 [96]. Further experiments are necessary; at present, it 
is not clear whether amylin replacement therapy, similar to leptin [31], restores 
the normal pattern of AP to NTS projections. Further, despite the 
neuroanatomical defect in the brain of early postnatal amylin-deficient mice, it is 
currently unknown whether these projections may develop later in life and 
whether they play a specific functional role in amylin’s inhibitory effect on eating. 
Because amylin-deficient mice eat less after exogenous amylin administration, 
and because exogenous amylin triggers c-Fos expression to a similar extent as 
in control mice, it is possible that some structural or functional changes 
compensate for the defective AP to NTS connections that we observed in early 
postnatal amylin-deficient mice.  Also, it has yet to be explored if the propensity 
of rats to develop DIO, or pre- and postnatal nutrition will modify amylin’s effect 
on these developing circuits, as seems to be the case for leptin [33, 34]. 
 
How the reward system comes into play 
A final point to consider when addressing how obesity and HFD may influence 
how the brain perceives and responds to gut and adiposity hormones controlling 
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food intake, is how the central reward system comes into play.  The 
mesoaccumbens dopamine (DA) system, which comprises the dopaminergic 
pathway projecting from the ventral tegmental area (VTA) to the nucleus 
accumbens (ACB), has been widely investigated in regard to its role in various 
components of reward, addiction, and food intake [98].  Numerous reports also 
suggest that this pathway is altered by obesity and the ingestion of highly 
palatable, high-energy diets. 
Extensive pharmacological studies have shown that the ACB contributes to 
multiple, dissociable components of feeding behavior that are dependent on the 
engagement of specific neurochemical networks within the nucleus ([99-104]. For 
instance, it has been suggested that DA transmission within the ACB is involved 
in stimulating food-seeking behaviors prior to interaction with the goal object 
(“wanting”), while an opioid network enhances the organism’s interaction with the 
food once it has been obtained (“liking”) [105]. Increased DA efflux in the ACB 
accompanies consumption of novel palatable food [106], and when rats are 
allowed intermittent access to sucrose pellets [107]; however, when given 
repeated or chronic access to palatable food, the effect disappears. Thus, while 
consumption of palatable food initially causes significant increases in ACB DA 
release, this response dissipates over time as the novelty of the food wanes 
[107]. Such effects are very interesting in respect to our experiments where rats 
were exposed to liquid Ensure (discussed below).  
The state of obesity also appears to effect DA levels in the ACB. Decreased 
basal and chow-induced extracellular DA levels in the ACB have been observed 
in DIO rats, as compared to lean rats [108].  Further, brain slices obtained form 
DIO rats demonstrated decreased electrically-stimulated DA release, suggesting 
a presynaptic deficit resulting from either decreased DA synthesis in VTA 
neurons [109], or decreased DA release and increased clearance in the ACB 
[108].  
An increasing amount of research supports the idea that the effects of obesity or 
palatable and high energy diets on the mesoaccumbens DA system is partially 
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caused by modulation of neurons of the VTA and ACB by the circulating 
hormones controlling energy homeotasis, e.g. by leptin.  Small doses of leptin 
administered directly to the VTA resulted in a suppression in food intake that 
corresponds to the anorectic effect of systemic or intracerebroventricular leptin 
[110].  A portion of dopaminergic neurons in the VTA have been shown to not 
only express LRb receptors [111], but also increased pSTAT3 following leptin 
administration [110, 112].  A small percentage of pSTAT3-positive neurons in the 
VTA were also shown to project to the shell of the ACB, suggesting that leptin 
may directly modulate DA release from the VTA to the ACB [112].  Furthermore, 
reduced electrically-stimulated DA release was observed in ACB brain slices of 
leptin-deficient Lepob/ob mice [112].  While decreased DA levels in leptin-deficient 
mice might appear to first contrast to the similar data described above in DIO 
rats, which are hyperleptinemic, it is actually not surprising that both models of 
rodent obesity, which are related to impaired function of the leptin system, show 
disruptions in mesoaccumbens DA release [113, 114].  While the mechanisms by 
which leptin can influence the mesoaccumbens DA system are not fully 
delineated, the effects of this hormone on a pathway intimately involved in food 
reward and palatability are evident.  
What about amylin? Although there is relatively little known about interactions 
between amylin and the reward pathways, enough data exist to advocate future 
studies in this direction.  Most interesting are studies demonstrating that some of 
the highest densities of amylin binding sites are located in the ACB [115-117]. 
However, since there is no evidence of amylin synthesis or release in the ACB, 
the functionality of these receptors remains unknown. Of note, amylin is able to 
cross the blood brain barrier by specific non-saturable transport [88]. Hence, it is 
in principle possible that amylin may reach neurons at these brain sites and exert 
effects which may be independent of amylin’s action at its main primary target 
site in the AP. 
Despite not knowing the physiological relevance of amylin binding in the ACB, it 
has been shown that amylin injected directly into the ACB produces a dose-
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dependent reduction in food intake, which may be related to a more general 
diminished state of arousal or exploratory behavior [118].  Furthermore, while 
amylin is known to not cause taste aversion or sickness to produce its eating 
inhibitory effects [43, 119], it has been shown to decrease lever-pressing for milk 
in mice, suggesting that amylin decreases the motivation to obtain milk [120].  
Finally, our recent data on the effect of amylin in rats that were exposed to a 
highly palatable liquid Ensure diet (see “Amylin sensitivity in the obese state”; 
[81]) may provide a direct link to reward related questions. In these experiments, 
amylin’s effect to reduce eating was markedly reduced in rats exposed to Ensure 
for few days; however, the effect was quickly reversible upon removal of Ensure, 
and the effect seemed to fade on more chronic exposure to Ensure. These 
findings provide interesting parallels to the studies showing increased DA efflux 
in the ACB on novel, but not on chronic exposure to palatable food [106, 107]. In 
other words, highly rewarding stimuli may produce a strong signal to the brain 
that cannot easily be overcome by amylin’s effect to acutely reduce eating, but 
that amylin is effective once this strong signal wanes. It would therefore be 
interesting to test whether acute blockade of the DA system in the ACB restores 
amylin’s effect to reduce eating even in rats with access to a novel, highly 
palatable stimulus. 
 
Summary 
Despite a complex and elaborate network that controls eating and energy 
metabolism, some of the components of this system appear to fail in obesity, i.e. 
when seemingly being needed most. Here, we discuss similarities and 
differences in the effects of amylin, leptin and CCK in obesity. We have to realize 
that at present, only very little is known about amylin pathophysiology in many of 
these respects. While leptin resistance, which is present in most cases of 
common obesity, has been traced back to defective transport systems for leptin 
across the blood brain barrier and to defects in LRb signaling, the exact reasons 
for a reduced sensitivity to the eating inhibitory effect of amylin are less clear. 
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Similar to leptin or CCK, chronic exposure to HFD seems to lower amylin 
sensitivity; however, whether reduced amylin receptor number or activity, or 
defects in intracellular signaling systems account for this effect, is unknown. 
Further, it is also not yet clear whether reduced sensitivity is specifically due to 
some dietary components rather than high energy content, as seems to be the 
case for CCK. Finally, amylin’s effect seems to be less prominent when rats are 
exposed to novel and highly palatable flavors, but the interactions between 
amylin and the (food) reward system require further studies. 
In clear contrast to leptin, we showed that chronically elevated amylin levels do 
not seem to downregulate the sensitivity of the amylin signaling system because 
amylin effectively reduced eating despite prevailing hyperamylinemia, which was 
induced independently of obesity or exposure to specific HFDs. We also 
addressed the aspect whether obesity or the exposure to HFD influence the 
secretion of amylin; however, at least the meal-induced increase in plasma 
amylin was comparable between DIO and DR rats, or in rats on a HFD versus 
chow diet. Hence, our experiments did not provide evidence for reduced amylin 
secretion under such conditions.  
Finally, we present recent findings on the trophic effects of leptin and amylin in 
their putative primary target areas. Similar to leptin, which acts as an important 
trophic factor for intra-hypothalamic neuronal projections, amylin may also be 
necessary for the proper development of brainstem pathways. However, the 
physiological relevance of this effect is unclear at present; in fact, this also seems 
to be the case for leptin because adult amylin-deficient mice react normally to 
exogenous amylin, just as leptin-deficient mice do to exogenous leptin. It has not 
yet been studied whether similar to leptin, amylin-sensitive pathways may also be 
affected in animal models of common obesity, such as the DIO rat. 
This brings us to an important question. Does the amylinergic system “explain” 
the obesity epidemic? In other words, is overeating and subsequent obesity 
caused by a lack of amylin secretion or action? We believe that the vast majority 
of data would not support such a statement. Defects in meal-induced amylin 
26 
 
secretion are unlikely to occur, and reduced amylin sensitivity which has only 
been observed under specific experimental conditions, apparently can usually be 
overcome by higher amylin doses. Hence, the amylinergic system may be less 
sensitive under some conditions, but it is not insensitive. This is important for any 
potential use of amylin-based drugs for anti-obesity therapy.  
Future studies will address in more detail the effect of specific dietary 
components and of obesity on the amylin secretory pathway, on amylin receptor 
components (CT-R; RAMP) and on amylin receptor signaling, i.e. the intracellular 
signaling systems mediating amylin’s effects. Finally, because amylin-deficient 
mice show a normal response to exogenous amylin, the biological relevance of 
amylin’s trophic effect on hindbrain neuronal projections also needs to be 
evaluated further. 
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